UCD is a life-threatening liver metabolism disorder which can affect newborns and infants, causing toxic levels of ammonia to accumulate in the body. This can lead to massive damage of the brain and nervous system. Cytonet's liver cell therapy has the potential to stabilize ammonia levels through infusion of healthy liver cells, potentially increasing the length of time children can safely wait until they can undergo a liver transplant.
"Every life we can save through Liver Cell Therapy is validation of our company's mission. This is a very significant milestone for us," said Dr.
Cytonet is conducting a clinical trial in the U.S. and
ABOUT UCD AND LIVER CELL THERAPY
For parents of babies born with UCD, the joy of giving birth to a perfect baby can quickly turn to devastation as the baby's health rapidly declines, going from symptoms such as being tired and irritable, to not eating, to experiencing seizures and coma.
Children left untreated for UCD rarely experience normal physical and mental development. The only cure currently available is liver transplantation, which can be an extremely difficult procedure for the very young. Additionally, there is a shortage of suitable organs available for transplantation.
Liver cell therapy involves collecting healthy cells from donated livers not suitable for transplantation which are then gently isolated and undergo complex processing. These cells are infused into the portal vein over six days.
Keywords for this news article include: Cytonet, Therapy, Treatment, Pediatrics, Clinical Trials and Studies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- Obama, Ukraine Discuss Russian Incursion in Crimea
- Chinese May Have Spotted Malaysia Airlines Debris
- Social Media Causee Sleep Deprivation in Students
- First-time Jobless Claims Drop Unexpectedly
- Banks Buying Little From Minority Firms: Study
- General Electric Plans IPO of Credit Card Unit
- SXSW Crash Kills 2, Injures 23
- U.S. Business Inventories Up, Retail Sales Down
- 'Candy Crush' Maker Files IPO
- First-time U.S. Jobless Claims Hit 3-month Low